Navidea to Present Late-Breaking Abstract at American College of Rheumatology Annual Meeting
November 01 2017 - 9:00AM
Business Wire
IV-Administered, Radio-labelled tilmanocept
Demonstrates Site-Specific Macrophage Localization in Rheumatoid
Arthritis Patients
Navidea Biopharmaceuticals (NYSE MKT: NAVB), a company focused
on the development of precision immunodiagnostic agents and
immunotherapeutics, announced today that it will present a poster
during the late-breaking abstract poster session at the American
College of Rheumatology (ACR) and Association of Reproductive
Health Professionals (ARHP) Annual Meeting, being held November
3-8, 2017, in San Diego, California.
Frederick O. Cope, PhD, MS, FACN, Chief Scientific Officer of
Navidea, will present a poster of an abstract, titled, “Evaluation
of Intravenous Injection of Tc 99m Tilmanocept in Static Planar
Gamma Emission Imaging and Fused SPECT/CT Imaging for Rheumatoid
Arthritis” and provide an overview of Navidea’s development
pipeline.
Event: ACR/ARHP Annual
Meeting
Date: Tuesday, November 7, 2017
Time: 9:00am
- 11:00am (Pacific Time)
Location: San Diego Convention
Hall, San Diego, CA
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
ManoceptTM platform to enhance patient care by identifying the
sites and pathways of disease and enable better diagnostic
accuracy, clinical decision-making, and targeted treatment.
Navidea’s Manocept platform is predicated on the ability to
specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the
molecular backbone of Tc 99m tilmanocept, the first product
developed and commercialized by Navidea based on the platform. The
development activities of the Manocept immunotherapeutic platform
are being conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver
superior growth and shareholder return by bringing to market novel
products and advancing the Company’s pipeline through global
partnering and commercialization efforts.
For more information, please visit www.navidea.com.
Forward-Looking Statements
This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. We have based these forward-looking statements
largely on our current expectations and projections about future
events and financial trends affecting the financial condition of
our business. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, including, among
other things: general economic and business conditions, both
nationally and in our markets; our history of losses and
uncertainty of future profitability; the final outcome of the CRG
litigation in Texas; our ability to successfully complete research
and further development of our drug candidates; the timing, cost
and uncertainty of obtaining regulatory approvals of our drug
candidates; our ability to successfully commercialize our drug
candidates; our expectations and estimates concerning future
financial performance, financing plans and the impact of
competition; our ability to raise capital sufficient to fund our
development and commercialization programs; our ability to
implement our growth strategy; anticipated trends in our business;
advances in technologies; and other risk factors set forth in this
report and detailed in our most recent Annual Report on Form 10-K
and other SEC filings. You are urged to carefully review and
consider the disclosures found in our SEC filings, which are
available at www.sec.gov or
at http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171101005969/en/
Navidea BiopharmaceuticalsJed Latkin, CFO/COO,
614-551-3416jlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024